Prof. Dr. Gideon Kersten joins Scientific Advisory Board of Coriolis

Prof. Dr. Gideon Kersten joins Scientific Advisory Board of Coriolis

Prof. Dr. Gideon Kersten is a vaccinologist with over 35 years of experience in vaccine development. His special interests are in characterization and formulation of biologicals. He joined the vaccine division of the Institute for Public Health in the Netherlands in 1985, where he was involved in the development of new vaccines and the improvement of existing ones. These included vaccines against polio, influenza, respiratory syncytial (RS) virus, Neisseria meningitidis type B and pertussis. Prof. Kersten was responsible for formulation development and vaccine characterization. Since 2012, he holds a special professorship in vaccine development at the Leiden University in the Netherlands. In 2017, Prof. Kersten became Chief Scientific Officer of Intravacc, a vaccine R&D institute. He has published over 100 peer reviewed scientific papers and book chapters and supervised 10 PhD students. He is a frequent lecturer at universities and during the Corona crisis he was frequently contacted by journalists to comment on vaccine related topics.

In 2020, Prof. Kersten joined Coriolis Pharma and we are proud to have his outstanding expertise now also available during his new function as Scientific Advisor. 

Prof. Kersten will actively be involved in project discussions and will contribute with his long-year experience to successful project outcomes. His advice will be provided independently from his affiliated university. This ensures the highest level of protection of our clients’ entrusted information. No additional contracts with the university are required to benefit from the scientific advice of Prof. Kersten.

Scientific highlights in Prof. Kersten’s (academic) career:

  • Proof of concept and contribution to development of Sabin-based inactivated polio vaccine, now marketed and WHO prequalified as Eupolio by LG of South Korea. E.g., Kersten et al. Vaccine 1999
  • Development of several vaccines to clinical stage, e.g., Neisseria meningitides type B, inactivated polio vaccine and RS virus vaccine. E.g., Arigita et al. Vaccine 2004, Westdijk et al. Vaccine 2013
  • Developing in vitro analytical fingerprinting methods of complex biologicals such as toxoid vaccines as alternatives for animal testing. E.g., Metz et al. Vaccine 2003, Michiels et al. Vaccines 2020
  • Using systems vaccinology approaches to unravel immune mechanisms of, e.g., Bordetella pertussis infections or alum-based adjuvants. E.g., Raeven et al. Plosone 2014, Kooijman et al. J Prot 2018
  • Developing needle-free administration routes for vaccines such as dermal microneedles, injected bioneedles, sublingual, pulmonal and intranasal. E.g., Leone et al. EJPB 2019, Soema et al. Plosone 2014, Kanoija et al. JCR 2018, Kraan et al. Vaccine 2017, Raeven et al. Plosone 2020

Further reading